Ultrasound-mediated synthesis, biological evaluation, docking and in vivo acute oral toxicity study of novel indolin-2-one coupled pyrimidine derivatives
- 26 Downloads
The work reports ultrasound-mediated greener synthesis of 11 novel 3-(4-(4-chlorophenyl)-6-(substituted phenyl/heteryl)pyrimidin-2-ylimino)indolin-2-one (7a–7k) derivatives. The synthesized derivatives were evaluated for their in vitro anticancer activity against a panel of selected human cancer cell lines of breast (MCF-7), cervix (HeLa), prostate (PC-3) and lung (A-549). Among the tested compounds, 7b exhibited most promising in vitro anticancer activity against HeLa, PC-3 and A-549 with GI50 value 15.38, 19.67 and 4.37 µM, respectively. The compounds (7a–7k) were also screened for induction of apoptosis and morphological changes in cancer cells at their GI50 concentration. The treatment of HeLa, PC-3 and A549 cancer cells with 7b and treatment of MCF-7 cancer cells with 7h showed apoptosis and morphological changes such as cell shrinkage, cell wall deformation and reduced number of viable cells. The compound 7b has shown almost 5.00 times more selectivity for PC-3 cancer cell lines in comparison to the RWPE-1 normal prostate epithelial cells. Molecular docking study has been carried out, which replicates results of biological activity in cases of initial hits 7b, 7c and 7d, suggesting that these compounds have a potential to become lead molecules in the drug discovery process. In silico ADMET study was performed for predicting pharmacokinetic properties and toxicity profile of the synthesized compounds and expressed good oral drug-like behaviour. An in vivo acute oral toxicity study was performed using Swiss albino mice for the most active compounds 7b and 7c, and results indicate that the compounds are non-toxic in nature.
KeywordsUltrasound mediated Indolin-2-one In vitro anticancer activity Molecular docking In vivo acute oral toxicity
The authors are thankful to Mrs. Fatima Zakaria, Chairman Maulana Azad Educational Trust and Dr. Zahid Zaheer, Principal, Y.B. Chavan College of Pharmacy, Dr. Rafiq Zakaria Campus, Aurangabad 431 001 (M.S.), India for providing the laboratory facility.
Compliance with ethical standards
Conflict of interest
The authors confirm that this article content has no conflict of interest.
- 11.Glaxo SK (2000) Combination of lapatinib with carboplatin, paclitaxel and trastuzumab in metastatic breast cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US) [cited 2015 Mar 06]. NLM Identifier: NCT00367471Google Scholar
- 12.Twenty eight clinical trials were found on clinicaltrials.gov (accessed in March 2015) site in which RTK inhibitors were being used in combination with antitubulins and other chemotherapeutic agents. Of these, 16 trials are currently in progress and the identification numbers in clinical trials.gov are provided below: NCT01855750; NCT01804530; NCT01606878; NCT01746277; NCT02326285; NCT01620190; NCT01974440; NCT01683994; NCT02378389; NCT01939054; NCT01719302; NCT02191059; NCT02191059; NCT01876082; NCT00567554; NCT00367471 (03/06/2015)Google Scholar
- 13.U.O. Vermont Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2015 Mar 06]. NLM Identifier: NCT01719302Google Scholar
- 25.R. Dudhea, P.K. Sharma, P. Verma, A. Chaudhary, J. Adv. Sci. Res. 2, 10 (2011)Google Scholar
- 31.B.G. Raimond, B. Gigant, P.A. Curmi, I. Jourdain, S. Lachkar, A. Sobel, M. Knossow, Nature 248, 198 (2004)Google Scholar
- 35.M.I. Nicoletti, G. Valoti, P. Giannakakou, Z. Zhan, J.H. Kim, V. Lucchini, F. Landoni, J.G. Mayo, R. Giavazzi, T. Fojo, Clin. Cancer Res. 7, 2912 (2001)Google Scholar
- 36.P.G. McKean, S. Vaughan, K. Gull, J. Cell Sci. 114, 2723 (2001)Google Scholar
- 40.E.S. Tamany, F.A. Shahed, B.H. Mohamed, J. Serb. Chem. Soc. 64, 9 (1999)Google Scholar
- 42.D. Lagorce, H. Sperandio, M. Miteva, B.O. Villoutreix, Bioinformatics 9, 396 (2008)Google Scholar